Log In

 

Company Name : Octapharma AG

Friday, March 2, 2018 11:30AM IST (6:00AM GMT)

(BW)(OCTAPHARMA-AG)

Octapharma Group Publishes 2017 Annual Results Reporting Revenue of €1.72 Billion and Operating Income of €349 Million


LACHEN, Switzerland

Over the last six years, the Octapharma Group has accomplished a remarkable compound annual growth rate of 15% and reports another record-breaking result for 2017, with sales of €1.72 billion – €120 million (7.5%) more than 2016’s figure (on a constant currency basis, the growth rate is 9.4%).

 

Gross profit in 2017 is €592 million. Operating income is €349 million. Net cash from operating activities is €353 million (20.5% of revenue). Trade receivables have remained stable despite the significant sales growth and our net inventory has increased by €57 million, to a comfortable holding of raw plasma.

 

Total operating expenses were €243 million, which includes significant investment in the future product portfolio: €87 million was invested in research and development (R&D) and €201 million in the extension of our production capacity and infrastructure. The significant investment made in research and infrastructure strongly positions Octapharma to fulfil the needs of more healthcare professionals and patients around the world.

 

To download the full Octapharma Group 2017 Annual Report visit the Octapharma Annual Report website: www.annualreport.octapharma.com

 

About Octapharma

 

The vision of Octapharma is “Our passion drives us to provide new health solutions advancing human life”. Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood. Our company values are Ownership, Integrity, Leadership, Sustainability and Entrepreneurship.

 

In 2017, the Group achieved €1.72 billion in revenue, an operating income of €349 million and invested €287 million to ensure future prosperity. Octapharma employs around 7,700 people worldwide to support the treatment of patients in 113 countries with products across three therapeutic areas:

 
  • Haematology (coagulation disorders)
  • Immunotherapy (immune disorders)
  • Critical care

Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden.

 

For more information visit www.octapharma.com

 

 

 

 


Click here for Media Contact Details
CONTACTS :

Octapharma AG
Claudie Qumsieh
Corporate Communications Manager
Office: +41 55 4512 121
claudie.qumsieh@octapharma.com


More News from Octapharma AG

23/01/2018 1:20PM

Octapharma: Low inhibitor rate with octanate® in previously untreated patients (PUPs) with severe haemophilia A

Octapharma is delighted to announce the publication of final data from a Good Clinical Practice (GCP) trial in PUPs in the internationally renowned medical journal Haemophilia. The study assessed the immunogenicity, ...

23/11/2017 10:55PM

Octapharma Donates 30.5 Million International Units of its Medicine Nuwiq to Treat People with Haemophilia in Developing Countries

2017: Octapharma is pleased to announce the completion of a charitable donation of 30.5 million international units of its human cell-line derived recombinant factor VIII product, Nuwiq®, in collaboration with ...

12/07/2017 11:30AM

Octapharma Symposium At ISTH Berlin Supports Progress in Lifelong Treatment of High-Risk Patients With Von Willebrand Disease (VWD) and haemophilia A

Octapharma is pleased to announce the success of yesterday’s symposium at the International Society on Thrombosis and Haemostasis (ISTH) congress held in Berlin, Germany. As platinum sponsors of the congress, ...

Similar News

21/09/2018 3:40PM

Leading Online Supplement Marketplace HealthXP Signs Sahil Khan as Its Brand Ambassador in India

HealthXP, India’s fastest growing online health, nutrition and sports supplement store is proud to announce its association with fitness icon Mr. Sahil Khan in India.

No Image

21/09/2018 1:38PM

Reissue: What Is Leaving Men Embarrassed & Putting Their Health on Stake

Common signs and symptoms of BPH include: Frequent or urgent need to urinate Increased frequency of urination at night (nocturia) Difficulty starting urination Weak urine stream or a ...